PGx-Guided Antiplatelet Therapy: Reducing Bleeding Risks with Personalized Dosing

Could personalized antiplatelet therapy unlock the door to substantial decline in bleeding complications during cardiovascular interventions?
The integration of pharmacogenomics into clinical practice has unveiled its substantial benefits for personalizing cardiovascular care. Specifically, tailoring the dosage of antiplatelet medications like clopidogrel through pharmacogenomics shows considerable promise in mitigating bleeding risks and the incidents of adverse drug events. Through evaluating an individual's genetic makeup, professionals are better equipped to optimize the application of antithrombotic agents, consequently enhancing clinical outcomes.
Evidence accentuates the practicality of adapting drug regimens based on genotype. A noteworthy 2019 study found that utilizing a genotype-driven approach for selecting P2Y12 inhibitors during primary percutaneous coronary intervention yielded enhanced results1. Moreover, genotype-based ...